<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The significance of flow cytometry indicating <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> without proof of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> by cytomorphology remains to be clarified </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated follow-up analyses in 142 patients analyzed in parallel by flow cytometry, cytomorphology and cytogenetics for suspected <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> without proof of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> by cytomorphology </plain></SENT>
<SENT sid="2" pm="."><plain>At initial assessment, flow cytometry indicated <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> in 64 of 142 (45.1%) patients </plain></SENT>
<SENT sid="3" pm="."><plain>In 9 of 142 (6.3%) patients, cytogenetics revealed aberrant karyotypes at first evaluation that were found in 5 of 64 (7.8%) patients rated with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> by flow cytometry </plain></SENT>
<SENT sid="4" pm="."><plain>The remaining 133 patients without proof of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> by cytomorphology and with <z:mpath ids='MPATH_458'>normal</z:mpath> karyotype underwent follow-up analyses that confirmed <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> by cytomorphology, cytogenetics or molecular genetics in 47 (35.3%) after a median interval of nine months (range 1-53 months) </plain></SENT>
<SENT sid="5" pm="."><plain>As far as initial flow cytometry results are concerned, this applied to 30 of 59 (50.1%) with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, 10 of 42 (23.8%) with "possible <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>" (minor antigen aberrancies only) and 7 of 32 (21.9%) without <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> (P=0.004) </plain></SENT>
<SENT sid="6" pm="."><plain>Notably, in these latter 7 patients, flow cytometry results changed at follow up to "possible <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>" (n=4) and "<z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>" (n=2) </plain></SENT>
<SENT sid="7" pm="."><plain>These data argue in favor of including flow cytometry along with cytomorphology, cytogenetics and molecular genetics to diagnose <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, and suggest a closer monitoring of patients with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-typical aberrant antigen expression found by flow cytometry </plain></SENT>
</text></document>